Predicting drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning.

It is crucial to be mindful of medications that may interfere with drug absorption, such as proton pump inhibitors and histamine receptor antagonists, as well as those that interfere with drug metabolism, such as CYP3A4 inhibitors and inducers. Additionally, special consideration should be given to populations at higher risk for polypharmacy, such as older patients with greater comorbidities. These interactions and patient characteristics should be considered when developing individual treatment plans with CDK4/6 inhibitors.